Physiological and pathophysiological role of somatostatin receptors in the human thymus

Diego Ferone1,3, P Martin van Hagen2, Rosario Pivonello1,3, Annamaria Colao3, Steven W J Lamberts3 and Leo J Holand1

1Department of Internal Medicine and 2Department of Immunology, Erasmus University, Rotterdam, The Netherlands, and 3Department of Molecular and Clinical Endocrinology and Oncology, `Federico II' University, Naples, Italy

(Correspondence should be addressed to D Ferone, Department of Internal Medicine, University Hospital Dijkzigt, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands)

Introduction

The functional interactions between the immune, endocrine and nervous systems occur at different levels, which underlie their relevance in controlling physiological processes. Any disturbances herein may be potentially involved in certain pathological conditions (1, 2). Studies in animal models have demonstrated that abnormalities in immune–neuroendocrine communications may start or contribute to the development of chronic autoimmune diseases. By analogy, similar questions have been raised for humans. Neuroendocrine and immune systems share a number of ligands and related receptors (3). The majority of these signalling molecules are highly conserved and, via these products, the systems in many species are able to establish sophisticated physiological intra- and inter-system communication circuits (4). The bidirectional neuroendocrine–immune interactions may constitute an important homeostatic mechanism (5).

In their physiological environment, immune cells are exposed to agents such as hormones and neuropeptides. These cells can produce hormones and neuropeptides themselves and may express specific receptors for neuroendocrine regulatory peptides as well (6–8). In addition, lymphoid tissues are directly and extensively innervated, the nerve fibres being in direct contact with lymphocytes or their precursors as well as macrophages, performing their neuro-effector functions.

In Table 1 the principal neuropeptides involved in controlling the immune system are indicated together with their effects on immune function. The distribution of neuropeptide receptors in the immune system has some common characteristics. Their expression pattern on different types of immune cells is heterogeneous, suggesting that the signal mediated by these agents can preferentially target different types of immune responses. Another important aspect is that the number or the activity of neuropeptide receptors on immunocytes may change during the specific and aspecific activation of these cells, suggesting that signals mediated by one of this effectors could be predominantly perceived by antigen-activated cells (1). This evidence may partially explain the rather common occurrence of conflicting observations that neuroendocrine-mediated activities exert on immune cells.

Many recent studies have pointed to the presence and functional roles of somatostatin (SS) and its receptors on the cells of the immune system (9, 10). SS is a peptide hormone widely distributed throughout the human body, involved in regulating neurotransmission in the brain, as well as secretion processes in the anterior pituitary gland, the pancreas and the gastrointestinal tract (11–13). An antiproliferative action of SS has been observed in many cell types in vitro as well (12). Five different SS receptor (SST) genes originate multiple SST subtypes (sst1–5) and, although the genes have a high degree of sequence homology, they are localized on different chromosomes, which allows a tissue-specific regulation of their expression and suggests diverse functions of the receptor subtypes in different organs (14–17). The five SST subtypes bind native SS with high affinity but can be further divided into two subclasses on their ability to bind structural octapeptide SS analogues. Three octapeptide SS analogues, octreotide, lanreotide and vapreotide, have already been introduced into clinical practice (Fig. 1). sst1 and sst4 receptors do not bind these analogues, whereas sst2A, sst3 and sst5 receptors display a high, low and moderate affinity, respectively, towards octapeptide SS analogues.

Among lymphatic organs, the thymus from different species, including the human, has been shown to contain the highest amount of SS (7, 8, 18). Although experimental models in animals have suggested the significant participation of different neuropeptides in the activities of the thymus, the exact role of SS in this context is still obscure.

SS and SST in the thymus

Structure and function of the human thymus

The thymus is a central lymphoid organ in mammals and it plays a pivotal role in the control of the immune system. The presence of the thymus and its functionality are required for full establishment of immunocompetence. The thymus involoves with constant velocity
during the first decade of life. Thereafter, the involution process decreases progressively (19). Connective and adipose tissues replace most of the thymic tissue, although some functional tissue remains throughout life (19, 20).

The thymus is covered by a thin connective tissue capsule and lobulated by septa originating from it. Septa, carrying vessels and nervous fibres, penetrate from the capsule to the central part of the organ designing the structure of cortex and medulla. These two regions can be distinguished because of the different density of the lymphoid cells. The medulla exhibits small and medium-sized lymphoid cells, as well as its typical Hassall’s corpuscles. The thymus has four principal cell types: thymocytes, the so-called ‘lymphocytes of the thymus’, which are the precursors of peripheral T lymphocytes; few macrophages and dendritic cells, which are all cells of bone marrow origin. The fourth type is a heterogeneous population of specialized thymic epithelial cells (TEC), which provide a supporting framework (the stroma) for the parenchyma. TEC, together with macrophages and dendritic cells drive the maturation and differentiation of thymocytes into mature lymphocytes, through cell-to-cell contacts and via soluble products. Thymic epithelium is a heterogeneous tissue, and cells in different locations within the lobules influence specific steps in thymocyte maturation. At least three phenotypically different types of epithelial cells are present in the thymus, cortical TEC, medullary TEC, and subcapsular epithelium. However, it seems that more subsets may be distinguished and identified on the basis of different content and type of cytokeratin (21).

Table 1 Effects of neuropeptides on immune functions.

<table>
<thead>
<tr>
<th>Neuropeptide</th>
<th>Immunoglobulin production</th>
<th>Cytokine secretion</th>
<th>Cell-mediated immunity</th>
<th>Inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenocorticotrophic hormone</td>
<td></td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Corticotrophin-releasing hormone</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Vasopressin</td>
<td></td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>β-Endorphin</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>α-Melanocyte-stimulating hormone</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Enkephalin</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Calcitonin gene-related peptide</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Nerve growth factor</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Somatostatin</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Substance P</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Vasoactive intestinal peptide</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
</tbody>
</table>

, increased response/activity; , decreased response/activity; , variable response.

Figure 1 Amino acid sequences of native SS-14 and synthetic stable octapeptide analogues octreotide (SMS 201–995), lanreotide (BIM23014) and vapreotide (RC-160). The darker shading indicates the amino acids essential for binding with the receptor.
Neuroendocrine control of the human thymus

Pituitary hormones, thyroid hormones, steroids and neuropeptides can indirectly and directly modulate thymocyte development, conveying positive and negative signals for thymocyte proliferation (24). Moreover, evidence that cytokine production by thymocytes may be under neuroendocrine control has been provided (25–27). The intrathymic production of many of these factors, as well as the expression of their specific receptors, has been characterized during recent years (Table 2). Thus, in addition to the classical endocrine pathways, paracrine and autocrine mechanisms are implicated in the influence of hormones and neuropeptides on the thymus (24). This strongly suggests that normal circulating levels as well as controlled local production of these factors are necessary to preserve the homeostasis and the various biological functions related to both the microenvironmental and lymphoid cells of this important organ. Recently, our research has been focused on SS and its receptors as clinical consequences of their local activity in the cross-talk between specific subsets of thymic cells in both normal and pathological events in the human thymus.

Distribution and significance of SS and SST in the human thymus

SS-binding sites have been demonstrated in various human lymphoid tissues (28, 29). Binding studies and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis have been used to characterize SS and SST subtype expression in the normal human thymus. SS and three SST subtypes, sst1, sst2A and sst3 have been found in thymic tissue (30). The expression of these different subtypes appeared heterogeneous within the tissue and on different cell subsets. A selective expression of sst1 and sst2A has been found on cultured TEC, in line with the evidence of [125I-Tyr3]-octreotide binding in the thymic medulla, where TEC is the prevalent cell type. TEC were also found to be a potential source of SS production within the thymus, since SS mRNA has been detected in these cells (30). Conversely, SS mRNA was undetectable in thymocytes and the distribution of SST subtypes on this heterogeneous cell population appears to be rather more complex (31). In fact, in freshly isolated thymocytes, sst2A and sst3 mRNA expression has been detected while, in long-term cultured thymocytes, no mRNA encoding for SST subtypes was detectable, suggesting a relatively rapid down-regulation of SSTs on thymocytes during culture (D Ferone, PM van Hagen, SWJ Lamberts & LJ Hofland, unpublished observations). Moreover, thymocytes at different levels of maturation seemed to express variable amounts of sst2A and sst3 mRNA compared with those in the whole population. In general, the number of SS-binding sites on thymocytes is low (32). This is in agreement with the presence of a low number of SS-binding sites on circulating human T lymphocytes (33), which derive from thymocytes. Finally, on macrophages.
the third thymic cell component examined, the presence of only sst2 A mRNA was detected (D Ferone, PM van Hagen, SWJ Lamberts & LJ Holland, unpublished observations). This finding is in agreement with previous reports showing the selective expression of SST subtypes in the thymus seems to follow a predisposed order related to the different stage of maturation of the lymphoid cells. On the other hand, SS and other neuropeptides have been reported to effectively modulate proliferation, cytokine production and antigen presentation by macrophages in the skin under physiological and pathophysiological conditions (44). The pattern of SST subtype expression on thymocytes seems to follow a predisposed order related to the different stage of maturation of the lymphoid cells. Moreover, sst1 is the SST subtype mainly expressed on thymocytes (D Ferone, PM van Hagen, SWJ Lamberts & LJ Holland, unpublished observations). Interestingly, this receptor seems to be selectively expressed on peripheral resting T lymphocytes, which directly derive from mature thymocytes (33). In the thymus, the majority of thymocytes are destined to die as a consequence of falling selection (45). Since cell death in the thymus occurs by apoptosis, the expression of the sst1 on these cells is intriguing. In fact, this SST subtype may be involved in agonist-mediated apoptosis (46). The presence of a receptor involved in this sophisticated

Table 2 Hormones, neuropeptides and their receptor expression within the thymus.

<table>
<thead>
<tr>
<th>Effector</th>
<th>Intrathymic production</th>
<th>Receptor expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>`Classic' hypothalamic peptides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GnRH</td>
<td>+</td>
<td>n.d.</td>
</tr>
<tr>
<td>GHRH</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>CRH</td>
<td>+</td>
<td>n.d.</td>
</tr>
<tr>
<td>TRH</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SS</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>`Classic' anterior pituitary hormones</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTH</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>GH</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>PRL</td>
<td>+</td>
<td>n.d.</td>
</tr>
<tr>
<td>LH</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>`Classic' posterior pituitary hormones</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasopressin</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Steroids and thyroid hormones</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortisol</td>
<td>n.d.</td>
<td>+</td>
</tr>
<tr>
<td>Oestradiol</td>
<td>n.d.</td>
<td>+</td>
</tr>
<tr>
<td>Progesterone</td>
<td>n.d.</td>
<td>+</td>
</tr>
<tr>
<td>Testosterone</td>
<td>n.d.</td>
<td>+</td>
</tr>
<tr>
<td>Tri-iodothyronine/thyroxine</td>
<td>n.d.</td>
<td>+</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>+</td>
<td>+ or −</td>
</tr>
<tr>
<td>Enkephalin</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>β-Endorphin</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>VIP</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>PACAP</td>
<td>n.d.</td>
<td>+</td>
</tr>
<tr>
<td>CGRP</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

GnRH, gonadotrophin-releasing hormone; GHRH, growth hormone-releasing hormone; CRH, corticotrophin-releasing hormone; TRH, thyrotrophin-releasing hormone; ACTH, adrenocorticotrophic hormone; GH, growth hormone; PRL, prolactin; LH, luteinizing hormone; VIP, vasoactive intestinal peptide; PACAP, pituitary adenylate cyclase-activating polypeptide; CGRP, calcitonin gene-related peptide; n.d., not detected.
process suggests a modulatory activity of SS in thymocyte deletion. However, further studies should elucidate whether SS might have an inductive or protective effect on programmed cell death in the human thymus. Recently, potent inducers of apoptosis in thymocytes, such as glucocorticoids, have been found to be implicated in the rescue of thymocytes from activation-induced cell death (47).

Emerging data are showing adhesion molecules, extracellular matrix ligands and receptors involved in driving thymocyte traffic, in terms of entrance of precursors, migration within the thymus, as well as exit of mature cells from the organ. This process seems to be influenced by neuroendocrine products as well (48–52). Since SS and other neuropeptides are involved in regulating the migration of immune cells in other compartments throughout the human body (53, 54, 55), and considering the peculiar distribution of SST within the thymus, SS might play a role in the modulation of this mechanism. This aspect may be important considering that a disturbance in this process could favour traffic of immature or wrongly selected cells towards peripheral lymphoid organs, enabling the development of autoimmune diseases.

The recent availability of antibodies specific for SST2A and SST1 receptors made it possible to further investigate the cellular localization of these receptor subtypes by immunohistochemistry in human lymphoid tissues (34, 35). In general, SST2A immunoreactivity has been found mainly located in areas where stromal cells are prevalent, while SST1 immunoreactivity occurred preferentially on cells with lymphoid morphology. The SST2A immunoreactivity, preferentially located in the medulla of the thymus is in agreement with the binding of the SST2-prefering ligand, [125I-Tyr3]-octreotide, detected by SST autoradiography, and with the expression of SST2A mRNA in isolated TEC (30, 31).

A final, but not less important, potential activity of SS within the thymus might be its involvement in the control of the physiologic involutive process that occurs in this lymphoid organ with ageing. The human thymus undergoes involution and decreases its activity in producing mature T cells. However, recent evidence points at the maintenance of an ‘endocrine’ activity of this organ, which might need a differential regulation during ageing (19). Binding studies with the SST1-prefering ligand [125I-Tyr3]-octreotide, evaluated in a large series of human thymuses by SST autoradiography and ligand binding on tissue homogenates, showed an inverse correlation between the number of SS-binding sites and the chronological age of the thymus (56). In fact, the score at autoradiography, as well as the number of SST at membrane homogenate binding (Bmax) were inversely correlated with the thymus age (P < 0.001). Further studies are required to clarify whether the decrease of SST in the human thymus during ageing is a programmed step during involution or whether it is a consequence of the process in itself (56).

The local production of SS in the human thymus seems to be extremely relevant since the neuropeptide might act at different levels, on different thymic cells and via different receptor subtypes. Within the human thymus, SS might be considered as a potential modulator of the homeostasis of various cell components as well as a regulator of their specialized activities. Moreover, SS seems to directly participate in the main thymic function, namely the maturation of the human T cell repertoire. The hypothesis of multiple functions of SS in the thymus is in line with the similar observation for another well-known neuropeptide, VIP. In fact, both SS and VIP are produced within this organ and a strong compartmentalization of their respective receptors has been shown on human thymic cells (57).

Like SST, the two VIP receptor subtypes display a distinct distribution in different thymocyte subsets, at least on murine and rat thymus, confirming that the expression of neuropeptide receptors could be differentially regulated during development (58). Finally, VIP may also affect multiple aspects of thymic cell functions (57, 58). An integrated role for these two neuropeptides, possibly together with substance P (SP), has already been hypothesized (28). However, the exact parameters regulating a hypothetical intrathymic circuit between these three substances have not yet been established. In general, in different pathophysiological conditions SS and VIP seem to ‘counteract’ the effect of SP on immune cells (58–60). However, in other situations, SS and VIP may have opposite effects on specific cell subsets, while acting synergistically on others (61).

The hypothesis on the relevance of SS and SST in thymus physiology discussed above form the basis for a better understanding of some mechanisms which may occur in pathological conditions of this organ.

**Distribution and significance of SS and SST in human thymic tumours**

Human thymoma is the most common tumour of the anterio-superior mediastinum and is composed of cytologically bland, neoplastic TEC accompanied by a variable admixture of benign lymphocytes (62). This tumour is frequently associated with paraneoplastic phenomena, such as myasthenia gravis, and/or other autoimmune-related disorders and haematological abnormalities (62). Like other tumours originating from SS-target tissues, human thymic epithelial tumours may express SST. These neoplasms have been visualized in vivo during SST scintigraphy using [111In-DTPA-d-Phe1]octreotide (63, 64). Although ligand-binding studies failed to detect SST on cryostat sections of human thymomas, at least three SST subtypes have been detected by immunohistochemistry using polyclonal antibodies specific for SST1, SST2A, and SST3 receptors (28, 65). Moreover, in one case the expression of SST subtypes was confirmed at mRNA level.
level by RT-PCR analysis (65). Since the number of receptors in normal thymic tissue as well as in thymoma is rather low, different sensitivity of the two methods might, in part, explain this discrepancy. Preliminary data showed the expression of sst2A and sst3 receptors in a series of human thymic tumours visualized by in vivo SST scintigraphy (D Ferone, PM van Hagen, SWJ Lamberts & LJ Hoanda, unpublished observations). Considerable heterogeneity of SST immunoreactivity was found within and among the tumours. The heterogeneity of SST expression and the density of different receptor subtypes might play a crucial role in determining the in vivo uptake of radiolabelled SS analogues. Preliminary data suggest that the presence of sst2 receptors is not an essential prerequisite for the visualization of SST-positive tissues during [111In-DTPA-d-Phe1]-octreotide scintigraphy (65). Moreover, sst3 receptors have been shown to display the highest amount of agonist-dependent receptor internalization compared with the other SST subtypes (66). Although the affinity of octapeptide SS analogues for sst3 is lower compared with that for sst2, the high internalization of sst3 receptors might be the possible mechanism regulating the in vivo uptake of [111In-DTPA-d-Phe1]-octreotide within thymomas. Indeed, sst3 seems to be the subtype predominantly expressed in thymomas. Another suggested hypothesis, which cannot be completely excluded, is the presence of a novel unidentified SST involved in determining the in vivo uptake of the radiotracer.

Receptor turnover and binding properties might be regulated differently in lymphoid cells compared with neuroendocrine cells. In fact, the activation of SST subtypes on lymphoid cells may induce opposite responses compared with endocrine cells (9, 10, 67). It has been suggested that thymocytes, which are the major cell population in the human thymus, can rapidly down-regulate the expression of their SST when cultured in vitro (29). Thymocytes are cells with a wide plasticity in terms of modulation and expression of surface molecules. From this point of view it would be interesting to investigate what happens in reactive thymocytes in thymomas.

In general, in light of these findings it may be hypothesized that, on the basis of its binding properties and receptor affinity, [125I-Tyr3]-octreotide may be considered as a clear sst2-preferring ligand for in vitro binding studies. In vitro, several exogenous factors may influence these properties, playing a role in determining the uptake of [111In-DTPA-d-Phe1]-octreotide within SST-expressing tissues and tumours as well. This is a point that may have important consequences for future applications of the currently available SS analogue for systemic radiotherapy, as well as for the development and use of novel subtype-selective analogues and antagonists. Data in the literature point to a certain efficacy of treatment with SS analogues in neoplastic diseases involving organs of the immune system and in autoimmune diseases (9, 10). Of particular interest is the reported successful treatment of patients bearing thymomas associated with paraneoplastic syndromes with the SS analogue octreotide or with the combination of octreotide and corticosteroids (64, 68). As far as the effect on the autoimmune disease is concerned, further studies should investigate whether the effect of therapy with SS analogues may have a rationale in the treatment of the severe autoimmune diseases, which are frequently associated with thymic disturbances.

The heterogeneity of SST expression pattern in thymic tumours and the reported effects on the tumour mass exerted by therapy with SS analogues might represent another stimulating field for future investigations. In fact, in one paradigmatic case displaying a significant in vivo uptake of [111In-DTPA-d-Phe1]-octreotide and a preferential expression of sst3 receptor, a significant inhibition of cell proliferation by SS and octreotide has been shown in vitro (65). SS is endogenously produced in the normal thymus, suggesting a role of the neuropeptide in controlling cell homeostasis in this organ. Conversely, in this thymoma SS mRNA was undetectable (65). Although very speculative, the loss of SS in a tumour arising from this organ might be involved in the pathogenesis of the neoplastic transformation as well as in the pathogenesis of the associated autoimmune diseases. However, as previously underlined, thymomas represent a highly heterogeneous class of tumours and further investigations are mandatory to elucidate the significance of SS and specific SST subtype expression in this class of tumours.

Conclusions

SST on target cells can be actively up- or down-regulated by exposure to several heterologous agents, as well as to its own ligand. In general, changes in the density, quality and activity of local regulatory factors might alter the distribution and concentration of neuropeptide receptors and their ligands. This may also apply to the human thymus, where the global activity of the organ is based on the balance of several regulating factors produced locally.

We can conclude that SS and a set of SST are expressed in the human thymus in both microenvironmental and lymphoid cells in an apparently selective manner. A highly specialized intrathymic circuit seems to integrate SS in the main function of this organ as well as in other activities, which needs further investigation. The age-related involution of this lymphoid organ and the occurrence of thymic tumour-related autoimmune diseases are two of the main aspects in which SS and SST might be involved. However, this points out the important role of the neuropeptide and its receptors in thymic homeostasis. The overall activity of the thymus is based on the balance of several regulating factors, which can be locally produced. Disturbances in this delicate equilibrium may lead to the induction of
unbalanced immune responses. Since alterations in the circuit involving SS might be implicated in the pathogenesis of these diseases, therapy with SS analogues might have an application in specific thymus-related immune disorders.

References


50 Delgado M, De la Fuente M, Martínez C & Gomariz RP. Pituitary adenylate cyclase-activating polypeptides (PACAP 27 and PACAP 38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP. *Immunology* 1996 89 70–76.


60 Stanisz AM, Befus D & Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyser's patches, mesenteric lymph nodes, and spleen. *Journal of Immunology* 1986 136 152–156.


Received 1 July 2000
Accepted 19 July 2000